Jeannie Hoffman-Censits
YOU?
Author Swipe
View article: Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors Open
Most new cancer diagnoses occur in patients over the age of 65. The composition and function of the immune system changes with age, but how the aged immune system affects responses to immune checkpoint inhibitor (ICI) cancer therapies rema…
View article: NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA
NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA Open
The optimization of dosing strategies is critical for maximizing efficacy and minimizing toxicity in drug development, particularly for drugs with narrow therapeutic windows such as antibody-drug conjugates (ADCs). This study demonstrates …
View article: Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma Open
Among patients with high-risk muscle-invasive urothelial carcinoma after radical surgery, disease-free survival was significantly longer with adjuvant pembrolizumab than with observation. (Funded by the National Cancer Institute of the Nat…
View article: Breaking Barriers: Addressing Issues of Inequality in Trial Enrollment and Clinical Outcomes for Patients With Kidney and Bladder Cancer
Breaking Barriers: Addressing Issues of Inequality in Trial Enrollment and Clinical Outcomes for Patients With Kidney and Bladder Cancer Open
Despite recent treatment advances, kidney and bladder cancer cases have continued to rise in both incidence and mortality over the last few decades. Not every demographic subgroup of patients diagnosed with these cancers has an equivalent …
View article: Penile sarcomatoid urothelial carcinoma: A case report
Penile sarcomatoid urothelial carcinoma: A case report Open
View article: Residual muscle-invasive disease at cystectomy is not accurately predicted by post-chemotherapy restaging protocols including DNA damage response gene mutation analysis
Residual muscle-invasive disease at cystectomy is not accurately predicted by post-chemotherapy restaging protocols including DNA damage response gene mutation analysis Open
View article: MP17-14 MOLECULAR CHARACTERIZATION AND RESPONSE TO THE IMMUNOTHERAPY OF SMALL CELL BLADDER CANCER
MP17-14 MOLECULAR CHARACTERIZATION AND RESPONSE TO THE IMMUNOTHERAPY OF SMALL CELL BLADDER CANCER Open
You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology II (MP17)1 Apr 2020MP17-14 MOLECULAR CHARACTERIZATION AND RESPONSE TO THE IMMUNOTHERAPY OF SMALL CELL BLADDER CANCER Woonyoung Choi*, Megan Fong, Jeannie Hof…
View article: cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC) Open
View article: First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy
First Report of NRG Oncology/Radiation Therapy Oncology Group 0622: A Phase 2 Trial of Samarium-153 Followed by Salvage Prostatic Fossa Irradiation in High-Risk Clinically Nonmetastatic Prostate Cancer After Radical Prostatectomy Open